GlassScriptPhysician profile
Michael J Lowney
NPI 1801946926
$3,922.21
in general payments reported to CMS, 2019-2025
25 companies · $745 in 2025
The $745 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $324 · 2021: $476 · 2022: $918 · 2023: $407 · 2024: $590 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,278.88 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.30 | 2021-2025 | Jardiance, Spiriva Respimat |
| Abbvie INC. | $441.30 | 2020-2025 | |
| Novo Nordisk INC | $312.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $220.08 | 2023-2025 | Eliquis, Camzyos |
| Lilly USA, LLC | $208.66 | 2022-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $191.99 | 2019-2020 | |
| Glaxosmithkline, LLC. | $124.77 | 2020-2023 | Trelegy Ellipta |
| Pfizer INC. | $109.76 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $81.10 | 2022-2025 | Rexulti |
| Genentech USA, INC. | $65.13 | 2020-2021 | |
| Esperion Therapeutics, INC. | $58.65 | 2021 | |
| Grt US Holding, INC. | $49.49 | 2022 | |
| Celgene Corporation | $44.94 | 2019 | |
| Astellas Pharma US INC | $32.95 | 2024 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $24.76 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.43 | 2025 | Caplyta |
| Ardelyx, INC. | $23.88 | 2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $23.45 | 2019 | |
| Aimmune Therapeutics, INC. | $21.80 | 2025 | Zenpep |
| Amgen INC. | $20.43 | 2019 | |
| Dermira, INC. | $15.02 | 2020 | |
| Hikma Pharmaceuticals USA | $13.08 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.08 | 2021 | |
| Philips North America LLC | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lowney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.